Medtronic is hiding behind its status as dividend aristocrat

The figures belie the prowess of Medtronic’s so-called “sustainable” and “broad-based” growth.
While all segments – cardiovascular, neuroscience, surgery and diabetes – did indeed post year-on-year sales gains, these were unfortunately entirely consumed by inflation in the cost structure.
Consolid…
© MarketScreener.com 2024